DrugMay 18, 2022
Amgen MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 recall — FDA D-0855-2022
Defective container: loose crimp defect, potential loss of container integrity.
Class IIFDA: TerminatedAmgen, Inc.
10,685drug recall records
953FDA Class I records
8firms with 5+ records
Aidapak Services, LLC537 records
Database records
Records — page 96
10,685 detailed records are currently available in this category.
DrugMay 18, 2022
Mylan Institutional Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg recall — FDA D-0861-2022
Failed Impurities/Degradation Specifications: OOS result was obtained for Any Other Individual Impurity at the 12M room temperature time point.
Class IIFDA: TerminatedMylan Institutional, Inc. (d.b.a. UDL Laboratories)
DrugMay 18, 2022
Fagron SyrSpend SF Suspending Base, Cherry Flavored recall — FDA D-0856-2022
Microbial Contamination of Non-Sterile Product: Product is contaminated with Burkholderia gladioli.
Class IFDA: CompletedFagron, Inc.
DrugMay 11, 2022
Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottles (NDC # 33342-045-07), b) recall — FDA D-0833-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 11, 2022
Losartan Potassium Tablets, USP, 25 mg, a) 90-count bottles (NDC # 33342-044-10), b) recall — FDA D-0832-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 11, 2022
Losartan Potassium Tablets USP, 100 mg, a) 90-count bottles (NDC# 68180-378-03), b) recall — FDA D-0840-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
McKesson Corporation dba McKesson Drug Company Lidocaine Hydrochloride Topical Solution USP recall — FDA D-0848-2022
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class IIFDA: OngoingMcKesson Corporation dba McKesson Drug Company
DrugMay 11, 2022
McKesson Corporation dba McKesson Drug Company Erythromycin Topical Gel USP, 2%, Net Wt 60 g recall — FDA D-0851-2022
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class IIFDA: OngoingMcKesson Corporation dba McKesson Drug Company
DrugMay 11, 2022
Losartan Potassium Tablets, USP, 100 mg, a) 30-count bottles (NDC # 33342-046-07), b) recall — FDA D-0834-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 11, 2022
Losartan Potassium Tablets USP, 50 mg, a) 90-count bottles (NDC# 68180-377-03), b) recall — FDA D-0839-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
Losartan Potassium & Hydrochlorothiazide Tablets, USP, 50 mg/12.5 mg, a) 30-count bottles recall — FDA D-0835-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 11, 2022
Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/12.5 mg a) 30-count bottles recall — FDA D-0843-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/25 mg, a) 30-count bottles recall — FDA D-0836-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 11, 2022
McKesson Corporation dba McKesson Drug Company Halobetasol Propionate Ointment 0.05% Net recall — FDA D-0847-2022
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class IIFDA: OngoingMcKesson Corporation dba McKesson Drug Company
DrugMay 11, 2022
McKesson Corporation dba McKesson Drug Company Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net recall — FDA D-0849-2022
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class IIFDA: OngoingMcKesson Corporation dba McKesson Drug Company
DrugMay 11, 2022
Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/25 mg a) 30-count bottles recall — FDA D-0842-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
McKesson Corporation dba McKesson Drug Company Betamethasone Dipropionate Ointment USP recall — FDA D-0850-2022
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Class IIFDA: OngoingMcKesson Corporation dba McKesson Drug Company
DrugMay 11, 2022
Losartan Potassium Tablets USP, 25 mg, a) 90-count bottles (NDC# 68180-376-03), b) recall — FDA D-0838-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg a) 30-count bottles recall — FDA D-0841-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugMay 11, 2022
Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/12.5 mg, a) 30-count bottles recall — FDA D-0837-2022
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Class IIFDA: TerminatedMacleods Pharma Usa Inc.
DrugMay 4, 2022
American Health Packaging Cyanocobalamin Injection, USP, 1000 mcg per mL, For Intramuscular recall — FDA D-0790-2022
Subpotent Drug: Out of specification for assay.
Class IIIFDA: TerminatedAmerican Health Packaging
DrugMay 4, 2022
Mylan Pharmaceuticals Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL recall — FDA D-0845-2022
Labeling: Missing label on the vial
Class IFDA: TerminatedMylan Pharmaceuticals Inc.
DrugMay 4, 2022
Olympia Compounding Pharmacy dba Olympia NB-243, Papaverine 30mg/ml recall — FDA D-0803-2022
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
Class IIFDA: TerminatedOlympia Compounding Pharmacy dba Olympia Pharmacy
DrugMay 4, 2022
Olympia Compounding Pharmacy dba Olympia T-50, Papaverine 8 mg/mL recall — FDA D-0820-2022
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
Class IIFDA: TerminatedOlympia Compounding Pharmacy dba Olympia Pharmacy
How to use this drug recall index
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
What the database can and cannot tell you
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.